

Press Release

Study shows VivoSight OCT could help Eyelid Cancer Surgery

Tuesday, 21 May 2013

In what is believed to be the first ever study to investigate OCT (Optical Coherence Tomography) imaging of skin cancers in the eyelids and skin surrounding the eye, the Dept of Ophthalmology, Maidstone and Tunbridge Wells NHS Trust have shown that OCT scanning can accurately reveal the margins of tumours.

The study, which was conducted using the market leading VivoSight OCT scanner manufactured by Michelson Diagnostics, showed a positive correlation between tumour margins located using OCT and histology, the 'gold standard'.

This breakthrough could ultimately lead to routine use of OCT scanning to plan delicate eyelid surgery operations, minimising the removal of healthy tissue critical to the patient. The VivoSight OCT scanner is already gaining acceptance in dermatology where it is being used to aid the diagnosis and treatment of skin cancer.

Basal Cell Carcinoma (BCC) is the commonest form of skin cancer, which if left untreated can cause extensive localised tissue destruction resulting in potentially disfiguring effects. Successful treatment requires effective tumour eradication with minimal removal of surrounding tissues.

This is particularly important when treating periocular BCC's of which 55,000 are diagnosed annually in the UK, as these are located on or close to the eyelid where excess tissue removal could result in loss of eye function and a negative cosmetic impact

In the 15 patient study the researchers pre-operatively measured the extent of the BCC tumour using the VivoSight OCT scanner comparing the results with histology sections post excision. The results showed a positive correlation of lateral tumour margins between the pre-operative VivoSight OCT measurement and histology.

In addition, when assessing the morphological features of BCC, "VivoSight allowed identification of BCC features with higher sensitivity and specificity compared with previous OCT systems"

The paper which is published in the British Journal of Ophthalmology* concludes that "In vivo OCT imaging is a valuable non-invasive diagnostic technique with potential clinical application in the preoperative assessment of tumour margin measurements and histological correlation of BCCs of the eyelids."

For more information visit www.vivosight.com

References

* Lucia Pelosini, Henry Barnabas Smith, John B Schofield, Adam Meeckings, Anish Dhital, Mona Khandwala, Br J Ophthalmol doi:10.1136/bjophthalmol-2012-303043

Press Release

For further information please contact;

Ola Olarimi
Michelson Diagnostics Ltd
1 Grays Farm Production Village
Grays Farm Road
Orpington, Kent BR5 3BD
United Kingdom
t: +44 (0) 208 308 1695, e: ola.olarimi@vivosight.com

Notes to editors

About Michelson Diagnostics

Michelson Diagnostics is a rapidly growing medical device company which has developed and brought to market a scanning device used to improve and accelerate care for patients suffering from non-melanoma skin cancer. Michelson Diagnostics' core product - the VivoSight® OCT scanner - is used by dermatologists to see below the surface of the patient's skin, allowing them to gather additional information about their patient's condition, and is the first of its kind available to dermatologists. Founded in 2006, Michelson Diagnostics designs highly innovative instruments using multi-beam optical coherence tomography solutions. The company is headquartered in Kent, England.

Further information about Michelson Diagnostics is available on the Internet at www.michelsondiagnostics.com or by email to enquiries@vivosight.com.

About Octopus Investments

(www.octopusinvestments.com) Octopus Investments, founded in 2000, is a leading investment specialist. We offer innovative core and satellite investment solutions to UK investors, and a wide range of funding options for exceptional companies.

Our core investments include a discretionary management service and a range of multi-manager multi-asset OEICs. These are complemented by our range of satellite solutions, including venture capital trusts, enterprise investment schemes and inheritance tax products. Each product has been designed to solve specific problems faced by financial advisers and their clients.

Our funding solutions cover the entire capital structure, from equity through mezzanine to senior debt, and we seek out outstanding management teams in unlisted companies with whom we can partner.

Octopus has built its business around three core pillars: customer led innovation, excellence in customer service and the quality of our people. We employ more than 200 people and currently have more than £2.5 billion in assets under management.

Octopus has won a number of awards for its products and customer service. We have twice been voted one of the best 100 SMEs to work for by the Sunday Times, and we are one of only two fund management companies to be AAA rated by financial advisers for customer service."

Octopus Media Enquiries:
Georgina Turner, Octopus Investments
t: +44 (0) 207 776 3180, e: GTurner@octopusinvestments.com